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Zusammenfassung 
 
Voraussagemodell von Transfusionen bei der 
operativen Therapie oraler Plattenepithelkarzinome 
 
Suthin Jinaporntham 
 
 
Ziel: Feststellung der Transfusionshäufigkeit bei der kurativen operativen Therapie oraler 
Plattenepithelkarzinome und die Entwicklung eines voraussagbaren Transfusionsmodells 
(Transfusion Prediction Model/TPM) 
 
Material und Methoden: Es wurden von 150 Patienten mit einem oralen 
Plattenepithelkarzinom retrospektiv Daten gesammelt. Ausgewertet wurden insgesamt 17 
deskriptive Variablen der Patienten. Um den TPM entwickeln zu können, wurden jedoch nur 10 
präoperativ erhobene Variablen durch eine logistische Regression analysiert. 
 
Ergebnisse: Insgesamt wurden 41 (27,3%) Patienten transfundiert. Die Medianzahl der 
transfundierten Erythrozytenkonzentrate war 2,0 (Variable 1-7). Das Verhältnis zwischen 
Bereitstellung zu Transfusion war 4,7:1. Die logistischen Regressionsanalysen ermittelten die 
Neck dissection und die Rekonstruktionsverfahren als die bedeutsamsten Variablen für den 
Bedarf einer Transfusion. Basierend auf diese beiden Variablen wurde ein TPM entwickelt. Mit 
dem TPM kann die Voraussage getroffen werden, dass Patienten die keine oder nur einseitige 
Neck dissection ohne Rekonstruktion benötigten, die niedrigsten Risiken hatten, eine 
perioperative Transfusion zu bekommen (1,7%-4,5%). Patienten, die eine beidseitige Neck 
dissection aber keine Rekonstruktion benötigten, besaßen ein mäßiges Risiko (11,2%). 
Patienten, die eine Rekonstruktion bekamen, besaßen die höchsten Risiken (22,7%-67,2%). 
Nach dem TPM wurde eine Richtlinie für die präoperative Vorbereitung der Transfusion erstellt. 
 
Schlussfolgerung: Durch die Benutzung des TPM, ist eine medizinisch und wirtschaftlich 
sichere präoperative Planung für den Bedarf einer Transfusion möglich. Um die Genauigkeit 
des TPM prüfen zu können, sollte eine prospektive Studie folgen.  
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Abstract 
 
Transfusion Prediction Model for Surgical Treatment 
of Oral Squamous Cell Carcinoma 
 
Suthin Jinaporntham 
 
 
Purpose: To determine the need for perioperative allogeneic blood transfusion in patients with 
oral squamous cell carcinoma who underwent curative surgical procedures and to develope a 
Transfusion Prediction Model (TPM). 
 
Material and Method: Data from 150 patients with oral squamous cell carcinoma who were 
treated surgically during 1998-2002 were retrospectively collected. Data included 17 variables 
were descriptively analyzed to describe the population. In order to develope the TPM, only 10 
variables available prior to surgery were analyzed with logistic regression analyses. 
 
Results: Overall, 41(27.3%) patients required blood transfusion. The median number of units 
transfused was 2.0 (range 1-7 units). Crossmatch to transfusion ratio was 4.7:1. Logistic 
regression analyses showed the need for neck dissection and the need for reconstruction were 
most significantly associated with transfusion requirement. Based on these 2 variables, the TPM 
was developed. The TPM predicted that patients who received no or unilateral neck dissection 
without any reconstruction had low risk of requiring transfusion (1.7%-4.5%). Patients with 
bilateral neck dissection without reconstruction had moderate risk (11.2%), and patients who 
received reconstruction had high risk (22.7%-67.2%) of requiring blood transfusion. Based on 
this TPM, a guideline for preoperative transfusion planning was developed. 
 
Conclusion: With the use of TPM, an appropriate and cost-effective transfusion planning is 
possible. However, a new prospective study to prove the accuracy of the TPM should be 
accomplished.    
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1. Introduction 
 
 
1.1. Historical Perspective 
 
                Since the prehistoric time of mankind, blood has been recognized as 
a vital element and the excessive blood loss from wounded animal or enemy 
was generally accepted to cause death [81]. The role of blood as a mystical vital 
element is referred to in Lecivitus 17:11 which reads, “The life of the flesh is in 
the blood. “, while the Chinese Neiching (circa 1000 B.C.) claims the blood 
contains the soul [45]. Egyptians took blood baths as a recuperative measure, 
and Romans drank the blood of fallen Gladiators in an effort to cure epilepsy 
[46].  The ancient Greeks believed that blood was formed in the heart and was 
circulated through the veins to the rest of the body where it was consumed. 
Arteries were part of an independent system transporting air from the lungs. 
Although Erasistratos (circa 270 B.C.) had imagined the heart as a pump and 
Galen (131-201 A.D.) finally proved that arteries contain blood, communication 
with the venous system was still not discovered. Blood, formed in the liver, 
merely passed through the blood vessels and heart on its way, as a one way 
route, to the periphery [81]. These teaching concepts remained in place for 
1400 years. It was not until 1682 that William Harvey discovered the circulatory 
system of blood [145], which is still our contemporary concept until today. 
  
                The realization that blood moved in a circulatory stream led to 
experiments on vascular infusion. In 1642, George von Wahrendorff injected 
wine [54], and in 1656, Christopher Wren and Robert Boyle injected opium and 
other drugs intravenously into dogs [82]. Being inspired from the experiments 
from Christopher and Robert Boyle, Richard Lower began his experiments on 
intravenous injections of drugs and substances into living animals [143]. In 
1665, he performed the first transfusion of bloods from the carotid artery of one 
dog to the jugular vein of another dog [57]. This experiment led to the 
transfusion of animal blood into humans. The first animal-to-human blood 
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transfusion was conducted by a physician of King Louis XIV Jean Baptist Denis. 
A 15- year-old boy who had been weakened by repeated phlebotomies received 
direct transfusion of a lamb’s blood on June15, 1667 [80]. According to the letter 
by Denis, the child was cured and apparently survived the heterologous 
transfusion without any evident unfavorable effects. Soon after that, Lower and 
Edmund King transfused a man with sheep’s blood in England on November 3, 
1667 and the man survived the transfusion well [31, 79].  
 
                Although the first two subjects transfused by Denis were not 
adversely affected, the third and fourth recipients both died. The death of the 
third subject was attributable to other causes. However, the forth case, following 
an initial transfusion of calf’s blood in an effort to cure his maniacal behavior 
without any improvement, the patient received a second transfusion 2 days later 
[56]. He developed a classic transfusion reaction and died 2 months later. Denis 
was charged with murder but he was exonerated by testimony that the patient’s 
wife had given him a soup with a powder in it, which, when given to a cat, 
caused death [30]. French physicians determined that transfusion was unsound 
and the Parliament of Paris passed a law on January 10, 1670, making blood 
transfusion illegal. Later, when two men died from transfusion in Rome, a 
special proclamation by the Pope banned the practice of transfusion in almost 
all parts of Europe. The English quietly discontinued all transfusion studies and 
would not begin them again until the early 1800s. These events put an end to 
practice of blood transfusion for 150 years [137]. 
 
                The beginning of modern transfusion research and therapy took place 
in 1818 by the London obstetrician James Blundell at Guy’s hospital. The 
frequency of postpartum hemorrhage and death distressed him, so that he 
began experimenting with transfusing blood in animals. He demonstrated that a 
syringe could be effectively used to perform transfusion, that the lethal effects of 
arterial bleeding could be reversed by the transfusion of either venous or arterial 
blood, that the injection of 20 cc. air into the vein of a small dog was not fatal, 
but that transfusion across species was lethal to the recipient [32]. Thus, 
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Blundell was the first to state that only human blood should be use for human 
transfusion. This latter conclusion  was confirmed in France by Dumas and 
Prevost, who demonstrated  that the infusion of heterologous blood into an 
exanguinated animal produced only temporary  improvement and was followed 
by death within 6 days [16]. Blundell is credited with carrying out the first 
human-to-human transfusion on September 26, 1818. The patient was in 
terminal stage due to pyloric obstruction caused by carcinoma. Despite initial 
apparent improvement, the patient died 2 days later [41]. Blundell’s technique of 
blood transfusion was repeated on other patients and was variably successful, 
with approximately 50% of patients surviving the procedure [17]. In all, Blundell 
performed 10 transfusions, of which 5 were successful. Four of the 
unsuccessful transfusions were performed on moribund patients. The fifth was 
performed on a patient with puerperal sepsis. Four of the successful 
transfusions were given for postpartum hemorrhage and the fifth was 
administered to a boy who bled following amputation [115]. Thus, transfusion in 
the latter half of the 19th century was neither safe nor efficient. There were still 
many attempts to render transfusion a more predictable procedure. In 1869, 
Braxton-Hicks performed a number of transfusions in women with obstetrical 
bleeding. Many of them were in terminal stage, and ultimately all died [65]. 
Frustration with blood as a transfusion product led to even more bizarre 
innovations. From 1873 to 1880, cow, goat, and even human milk were 
transfused as a blood substitute [97]. Fortunately, these practices were 
discontinued as Bull advocated the use of saline solutions for blood volume 
replacement in stead of the more dangerous and unpredictable transfusion of 
blood [19].  
 
                In 1900, Karl Landsteiner observed that the sera of some individuals 
agglutinated the red cells of others. This study, published in 1901 in the Wiener 
Klinische Wochenschrift [70], revealed for the first time the cellular differences 
in individuals from the same species, i.e., the identification of blood groups. 
With the identification of blood group A, B, and O by Landsteiner in 1901 and of 
group AB by De castello and Sturli [29], the stage was set for the performance 
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of safe transfusion. However, at that time, the effective transfer of blood from 
one individual to another remained a very difficult procedure. Clotting, 
uncontrolled, quickly occluded transfusion devices were still frustrating. 
 
                In 1905, Alexis Carrel introduced the technique of end-to-end 
vascular anastomosis with a triple-threaded suture. This procedure brought the 
ends of vessels in close apposition and preserved luminal continuity, thus 
avoiding leakage or thrombosis [22]. This technique was adapted by Walker 
Carrel [134] and others to the performance of blood transfusion. Crile, one of 
surgical pioneers, introduced the use of an intraluminal metal cannula to 
facilitate the placement of sutures of end-to-end vascular anastomosis in 1907 
[26], and Bernheim used a two-pieced cannula to connect the artery to the vein 
[12]. Because all of these procedures usually culminated in the sacrifice of the 
two vessels and were often very difficult or even unsuccessful, they were not 
performed frequently. Moreover, there was still disadvantage that the performer 
could not know the amount of blood he had transfused or when to stop the 
transfusion unless the donor collapsed [104]. 
 
                Despite these difficulties, direct transfusion via arteriovenous 
anastomosis, for the first time, efficiently transferred blood from one individual to 
another. However, there was also a report of fatal hemolytic reactions that were 
undeniably caused by direct transfusion [108]. The relationship of these fatal 
reactions to Landsteiner’s discovery was still not recognized until Reuben 
Ottenberg demonstrated the importance of compatibility testing. He learned the 
Landsteiner’s discovery and began pretransfusion compatibility testing in 1907 
[102]. He continued his studied of transfusion and published the report that 
demonstrated the important of preliminary blood testing for prevention of fatal 
hemolytic transfusion reactions in 1913 [105]. He also observed the relative 
unimportance of donor antibodies and, consequently, the universal utility of type 
O blood donors [103].   
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Despite the introduction of compatibility testing by Ottenberg, 
transfusion could not be performed frequently as long as arteriovenous 
anastomosis remained the procedure of choice. New techniques, such as 
Unger’s two syringe method introduced in 1915 [131], eventually put an end to 
transfusion by arteriovenous anastomosis. 
 
                The Rhesus (Rh) system was discovered by Landsteiner and Wiener 
[71] in connection with an unusual transfusion reaction reported by Levine and 
Stetson in 1939 [75]. This discovery became one of the major advances in 
public health. The M, N, and P systems were described in the period between 
1927 and 1947 [28]. 
 
                It was not until the development of anticoagulants that blood 
transfusion become commonplace and direct transfusion from one individual to 
another were rendered obsolete. Early reports from Hustin [58] and Agote [1] in 
1914 and 1915 were followed by the work of Lewisohn in 1915 that 
recommended the optimal citrate concentration for anticoagulation, which 
allowed blood to be stored for prolonged period [76]. The work of Weil then 
demonstrated the use of refrigerated blood combined with the addition of 
sodium citrate enabled the banking of blood and obviated the need for direct 
transfusion [140]. Subsequently, Rous and Turner developed the anticoagulant 
solution that was used during World War I [116, 113]. Despite its very large 
volume, this solution remained the anticoagulant of choice until the 
development of an acid-citrate-dextrose (ACD) solution by Louti and Mollison 
during World War II [78]. 
 
                Separation of blood into its components led to component and 
derivative therapy, which began during World War II, when Edwin J. Cohn and 
his colleagues developed the cold ethanol method of plasma fractionation [25]. 
As result of their work, albumin, gamma-globulin and fibrinogen became 
available for clinical use. The introduction of plastic bags and equipments by 
Gibson and colleagues [47] allowed the convenient separation of blood 
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components and thus replaced the use of glass systems. These developments 
rendered the blood component separation and blood component therapy more 
practical and became commonplace. The introduction of automated cell 
separators provided even greater capabilities in this area.  
 
                Clotting factor concentrates for the treatment of patients with 
hemophilia and other hemorrhagic disorders were also developed during the 
postwar era. Although antihemophilic globulin had been described in 1937 
[106], unconcentrated plasma was only the therapeutic material until Pool 
discovered that factor VIII could be harvested in the cryoprecipitable fraction of 
blood [109].  This resulted in the development of cryoprecipitate, which was 
introduced in 1965 for the treatment of hemophilia.  Pool showed that 
cryoprecipitate could be made in a closed-bag system and urged its harvest 
from as many donations as possible. The development of cryoprecipitate and 
other concentrates was the great advancement in the care of patients with 
hemophilia and other hemorrhagic disorders. 
 
                In the early of the 20th century, transfusion has become safe and 
easy. The introduction of new anticoagulants and modern technologies led to 
the era of modern blood banking. Blood banks were founded in Europe and in 
the North America and the number of blood transfusions increased 
exponentially everywhere. 
 
 
1.2. Concern for Blood Safety 
 
                Although blood transfusion has saved countless lives, they can 
themselves also cause significant complications and even death. The 
transfusion risks are following.     
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1.2.1. Transfusion Reactions 
 
                Hemolytic transfusion reactions are serious complication and can be 
fatal. Most of them were caused by ABO-incompatibility, which occurs at a 
frequency of 1:27,000 to 1:135,207 [77, 60, 6].  About 2.11-7.06% of these 
cases were fatal [77, 6, 141, 23]. The frequency of fatality due to ABO-
Incompatibility has been estimated to be 1:800,000 units of blood [120], 
compared with approximately 1:2,000,000 transfusion for transmission of HIV 
[49]. The FDA reported a mistransfusion-related death rate that was more than 
2 times greater than that due to all infectious hazards combined, and the U.K. 
surveillance system reported an adverse event rate attributed to mistransfusion 
that was 10 times higher than the rate attributed to infectious disease 
transmission [95]. Approximately 50% of the errors are clinical errors such as 
incorrect identification of the recipient, sample collection error, and incorrect 
ABO-bedside testing [120]. Ahrens et al. reported incorrect ABO-bedside testing 
[2] as the most frequent clinical error, as also from many reports. The reported 
incidence of laboratory errors is extremely variable from 8 - 31% [6, 120,123,35, 
89, 8, 124]. 
 
                Febrile nonhemolytic transfusion reactions are generally not life 
threatening, with the estimated frequency at 0.5 % per unit of blood component 
transfused [135, 87]. Immediate allergic reactions, usually urticaria, occur in 1-
3% of recipients of plasma infusion [50]. Anaphylactic shock has an incidence of 
1:20,000 to 1:50,000 transfusions [135]. The transfusion-associated Graft-
versus-Host disease is very rare adverse reaction to blood transfusion in some 
immunocompromised patients [51]. 
 
 
1.2.2. Transmission of Infectious Agents 
 
                The first reports of transfusion-transmitted hepatitis appeared in 1943 
by Beeson [10], Morgan and Williamson [91]. After that, intensive investigations 
were done to identify the existence of hepatitis viruses, leading to the 
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subsequent definition of hepatitis A virus (HAV) [37] and hepatitis B virus (HBV) 
[27]. The recent discovery of hepatitis C virus (HCV) [24] filled the gap made by 
non-A non-B diseases. The implementation of third generation hepatitis B 
surface antigen screening test led to a marked reduction in transfusion-
transmitted hepatitis B [34]. The transmission of hepatitis B has been further 
reduced through effective screening tests for viral antibodies. In the 1980s the 
incidence of posttransfusion hepatitis decreased to 1-3% from 10% in the 1970 
[86]. The implementation of a test for HCV antibody in 1990 has further 
decreased the risk of posttransfusion hepatitis C [3], which is the predominant 
cause of transfusion-associated hepatitis. 
 
                 Hepatitis A transmission by blood transfusion is very rare due to the 
lack of a chronic carrier state and the presence of symptoms that would exclude 
blood donation during the brief viremic phase of the illness. The risk is 
estimated to be 1:1,000,000 units [33]. 
 
                The first report of transfusion-associated HIV infection in a 20-month-
old infant in 1983 [5] prompted blood banks to implement donor education and 
self-exclusion from blood donation. After the introduction of HIV antibody testing 
in 1985, only about 5 cases of transfusion-associated HIV infection were 
reported per year during the subsequent 5 years, compared with 714 cases 
reported in the year before HIV testing [121]. After the beginning of HIV antigen 
testing in 1995, only 2 blood donors (P24 antigen positive / anti-HIV negative) 
were found after 1 year of screening, of approximately 6,000,000 donations 
[125]. In recent years, blood centers have implemented nucleic acid 
amplification test (NAT) of minipools from blood donations to reduce HIV and 
HCV transmission during the window period of infection. Current estimated risk 
per unit of blood in the post-NAT era is approximately 1:1,900,000 for HIV and 
1:1,600,000 for HCV [49, 21, 7]. In contrast to the success at risk reduction of 
HIV and HCV, the risk of HBV transmission remains approximately 1:50,000 to 
1:150,000 in western countries. 
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                In 1999, the West Nile Virus (WNV) infection was detected as an 
epidemic meningitis and encephalitis in the USA. Blood transfusion was one of 
the new modes of infection recognized in 2002 [117]. There were 23 cases of 
transfusion-associated WNV from 14 donors between August 2002 and January 
2003 [107]. The mean risk of WNV by transmission was estimated to be 146 to 
1,233 per million donations [13]. 
 
                Cytomegalovirus (CMV) infection may be very severe in 
immunocompromised patients after transfusion of blood containing the virus or 
in patients scheduled for transplantation. CMV antibody testing is the gold 
standard to identify potentially infectious donors [52]. 
 
                The greatest risk of transfusion-associated bacterial infection is the 
contamination of platelets. Culture surveillance suggests that bacterial 
contamination of platelet concentrates and apheresis platelets occurs in 
approximately 1:1,000 to 1:2,000 units [144, 73].      
 
                Other infectious agents such as Epstein-Barr virus, Leishmaniasis, 
Lyme disease, Brucellosis, Malaria, Babesiosis, Toxoplasmosis, Chagas 
disease are rarely transmitted via transmission [48]. 
 
 
1.2.3. Transfusion-Related Acute Lung Injury 
 
                Transfusion-related acute lung injury is an acute respiratory distress 
syndrome that occurs within 4 hours after transfusion and is characterized by 
dyspnea and hypoxemia due to noncardiogenic pulmonary edema. Although the 
actual incidence is not well known and its occurrence is almost certainly 
underreported, its estimated frequency is approximately 1: 5,000 transfusions 
[110]. In a recent review, 11 cases of transfusion-related acute lung injury were 
recognized over 12 years [136]. 10 of 11 cases required mechanical respiratory 
support and 5 patients died. In 10 cases the transfused unit was plasma, with 
an observed incidence of 1: 7900 units. The authors concluded that transfusion-
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related acute lung injury is the most common serious adverse event in their 
hospital. 
   
 
1.2.4. Transfusion-Induced Immunosuppression 
 
                Immunosuppressive effects of blood transfusions were noted as early 
as 1973 by Opelz et al. [99], when renal allograft survival was found to be 
substantially improved in patients who had received preoperative blood 
transfusions. The authors postulated that this effect is secondary to 
immunosuppression induced by exposure to antigen expressed by transfused 
white blood cell, therefore decreased graft rejection. It has been widely 
accepted that allogeneic blood transfusion can improve renal allograft survival 
following transplantation [100, 98]. In 1980, Fischer et al. [40] demonstrated 
transfusion-induced suppression of cellular immunity in prospective study 
among renal transplant patients. After transfusion of 1 unit of allogeneic blood, 
mitogenic response and cell mediated hypersensitivity were reduced. Additional 
transfusions produced a more profound effect, suggesting a dose response. In 
contrast, patients receiving autologous blood did not show impaired cellular 
immunity. In contrast, allogeneic blood transfusions during surgery have not 
been shown to affect subsequent renal allograft survival [100]. Fernandez et al. 
[38] found significant immunosuppression among patients undergoing surgery 
for peripheral vascular disease who received transfusions compared with a 
similar group who did not. Among patients receiving blood, T4 lymphocyte 
counts decreased, and no rebound increase in the proliferation response 
occurred up to 90 days postoperatively. 
 
                The possible association between allogeneic blood transfusions and 
cancer recurrence was first suggested by Gantt [44] in 1981, who raised 
concern that patients undergoing curative surgery for a malignancy might be 
affected adversely by the immunosuppressive effects of allogeneic blood 
transfusion which were administered perioperatively. He also suggested that 
immunosuppression may cause shorter survival and disease-free interval in 
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cancer patients. Since then, many reports have described the effects of 
perioperative allogeneic blood transfusions on tumor recurrence and/or overall 
prognosis in patients with a malignancy who are undergoing curative cancer 
surgery. In 1982, Burrows and Tartter [20] reported an increased rate of 
recurrent colon cancer in a series of 58 transfused patients compared with 65 
nontransfused patients. At each tumor stage, patients receiving transfusions 
had a significantly higher recurrence rate. Foster et al. [42] noted that overall 
survival in patients treated for colon cancer was significantly higher in patients 
who had not received allogeneic transfusions when compared with patients who 
had. The relative risk of death due to cancer in patients with versus without 
transfusions was 2.3 when controlled for age, sex, stage, histologic grading, 
and cancer location. Blumberg et al. [14] performed a retrospective study in 
patients with colon carcinoma. They found that recurrence developed in 9% of 
68 patients who did not receive transfusions when compared with a 43% 
incidence of recurrence in 129 patients who received transfusion. In 1985, 
Hyman et al. [59] noted a significant decrease in survival time in patients 
underwent resection for lung cancer who received allogeneic blood transfusion 
when compared with patients in the same group who did not receive 
transfusion. Recently, Langley et al. [72] suggested that blood transfusion may 
have a significant adverse effect on late survival after esophageal resection for 
carcinoma in a study of 234 consecutive patients. In addition, several studies 
have shown increased tumor recurrence with perioperative allogeneic blood 
transfusion in patients with cancer of lung [129], breast [130], and soft tissue 
sarcomas of the extremities [114]. 
 
                Some clinical investigators could not found the relationship between 
perioperative blood transfusion and increased tumor recurrence or decreased 
survival rate. Foster et al. [43] did not found any correlation between transfusion 
and survival in patients treated for breast carcinoma. Nozoe et al. [96] failed to 
demonstrate the significance of allogeneic blood transfusion on decreased 
survival in 259 patients with esophageal carcinoma. Vente et al. [132] have 
performed a prospective study in 158 patients with colorectal cancer who were 
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transfused and 54 patients who were not. He could not confirm the deleterious 
effect of perioperative blood transfusion on survival. Similarly, Ota et al. [101] 
could not found significant difference in five- and ten-year survival rate between 
patients with colon carcinoma who received perioperative blood transfusion and 
patients who did not. 
 
                In head and neck cancers, there were several reports on adverse 
effect of allogeneic blood transfusion on tumor recurrence and survival rate. 
Johnson et al. [64] retrospectively analyzed 179 patients with stage III 
squamous cell carcinoma of the head and neck who underwent surgery. He 
found that blood transfusion may have a detrimental effect to survival rate. 
Jackson and Rice [62] reviewed 100 consecutive patients with head and neck 
cancer and found that the recurrence rate for all cancers of the larynx was 14% 
for those who did not receive blood and 65% for those who did. For cancer of 
oral cavity, pharynx, and nose or sinus, the recurrence rate was 31% without 
transfusion and 71% with transfusion. Jones and Weissler [66] performed a 
multivariate analysis of blood transfusion and 15 other variables using 
recurrence as the dependent variable in stage III to IV cancer of head and neck. 
They found margin status and allogeneic blood transfusion to be the significant 
predictors of recurrence. Wooley et al. [142] performed a multivariate logistic 
regression to determine the effect of transfusion on recurrence of squamous cell 
carcinoma of the supraglottic larynx or hypopharynx in 143 patients with stage II 
to IV. They found transfusion, number of pathological nodes, and preoperative 
hematocrit were significantly related to recurrence. They also performed a 
meta-analysis of the data from their study and five published studies and found 
a significant effect of blood transfusion on recurrence of head and neck cancer. 
In a study of 207 patients who underwent surgical resection of head and neck 
squamous cell carcinoma, Barra et al. [9] found in their multivariate analysis that 
transfusion was related to a higher risk of tumor recurrence. Alun-Jones et al. 
[4] found significance between allogeneic blood transfusion and recurrence in 
69 patients who had laryngeal cancer without nodal metastasis. Recently, 
Taniguchi and Okura [128] investigated the effect of perioperative allogeneic 
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transfusion on survival in stage II to IV squamous cell carcinoma of the oral 
cavity in consecutive 105 patients undergoing primary tumor resection and neck 
dissection. They found that, among 16 variables, the number of positive nodes 
and transfusion of 3 units or more of red blood cell were independent prognostic 
indicators on survival in multivariate analysis. 
 
                Some other studies, in contrast, have not confirmed the association 
between blood transfusion and recurrence in head and neck cancer patients. 
Von Doesten et al. [133] found transfusion status to be not significant after 
multivariate analysis. However, transfusion was found to be a significant 
predictor of postoperative infection. Boeck et al [18] found that patients requiring 
transfusion had a shorter survival than those who did not, but when adjusted for 
tumor size and lymph node metastasis, transfusion lost its significance. 
Similarly, McCulloch et al. [85] evaluated the role of blood transfusion in 166 
patients with head and neck cancer who were treated with surgery and 
postoperative radiotherapy. Blood transfusion was among many variables, 
which were significant to survival. However, they failed to show the significant 
relationship between blood transfusion and survival in stepwise multivariate 
models. Sturgis et al. [126] also showed in his backward stepwise multivariate 
regression model that transfusion have no influence on recurrence of head and 
neck cancer.  
 
                The risk of bacterial infection in patients after surgery who received 
allogeneic blood transfusion has been reported to be 25% to 30% compared to 
5% to 10% of patients received autologous blood [15]. Robbins et al. [112] 
reported a significant relationship between wound infection in head and neck 
surgical patients who undergoing clean-contaminated procedures who required 
blood transfusion. Weber et al. [139] found transfusion to be independently 
associated with an increased risk of postoperative pulmonary infections in 
multivariate analysis. Murphy et al. [94] showed a dose response between the 
number of allogeneic units transfused and postoperative infections among 
coronary bypass patients. In a case controlled study comparing infection rates 
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for patients receiving allogeneic versus autologous transfusions for the same 
surgical procedures, Mezrow et al. [88] found a significant difference in rates of 
positive cultures in the former group (16%) , compared to 4% in the latter group. 
In contrast, Boeck et al. [18] reviewed the infection rates among 151 patients 
underwent laryngectomy and found that the infection rates were not significantly 
different between patients who received transfusion and patients who did not. 
Von Doersten et al. [133] found that allogeneic transfusion was associated with 
an increased infection rate, but this failed to be significant in logistic regression 
analysis. 
 
 
1.3 Transfusion Needs in Surgery 
 
                A multimodal approach to managing blood loss in surgical patients 
was described by Krause and Heymann in 1910 [68]. They suggested several 
means for managing hypovolemia caused by surgical blood loss, including the 
administration of caffeine for its cardiostimulant and diuretic properties. They 
also advocated the use of digitalis as an inotrope and epinephrine as a 
vasoconstrictor. Intravenous physiologic salt solutions were used to restore 
intravascular volume, and extremity tourniquets were applied to autotransfuse 
patients. As a last resort for treating anemia secondary to blood loss, direct 
transfusion was performed between two persons from the radial artery of the 
donor via cannula to the cephalic vein of the recipient. The end points for 
termination of the direct transfusion were either donor faintness or a decrease in 
the donor’s systolic blood pressure to 100 mmHg. 
 
                In contemporary head and neck surgery, blood transfusion and the 
use of parenteral antibiotics have greatly decreased surgical morbidity and 
allowed the surgeon increased latitude in resecting advanced cancers. 
Describing the management of blood replacement in head and neck surgery, 
Hayes Martin [83] advocated no predetermination of the amount of blood to be 
given; however, blood replacement was to commence as soon as the operation 
got underway or as directed by the anesthesiologist based on the patient’s 
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blood pressure and systemic factors. Though Martin admitted that this was an 
expensive practice, he believed that the patient’s sense of well being, wound 
healing, and early discharge from the hospital were promoted by a replacement 
of blood equal to the loss. Total replacement might entail one transfusion for a 
standard neck dissection or up to 4 to 5 liters of blood for more extensive 
operations. In major procedures that include resection of a primary tumor in the 
upper aerodigestive tract and simultaneous neck dissection, blood transfusion 
may be required in more than 50% of patients [119, 36]. 
 
                McCulloch et al. [84] reviewed 77 patients underwent major surgical 
resection for head and neck cancer. They reported that maxillectomy / midface 
procedure showed the highest average blood use (1.8 +/- 1.0 units), followed by 
composite resection (1.4 +/- 1.4 units) and laryngectomy (1.3 +/- 2.2 units), 
while isolated neck dissection required averagely 0.4+/- 0.9 unit. Leong and 
Chew [74] studied blood loss and transfusion in 63 patients underwent major 
head and neck surgical procedures. They reported the average blood use 
during composite resection in head and neck tumor surgery and maxillectomy to 
be 2.3 and 1.4 units accordingly.  
 
In routine practice, surgeon usually orders blood for perioperative use 
according to experience of the institute where he works without knowing exactly 
the historic data of transfusion requirements for each specific surgical 
procedure. This leads to excessive amount of blood typing and cross matching 
because surgeon tends to feel safe for the patients, when he orders too much 
units of blood instead of not enough. As the modern operative and 
anesthesiologic techniques to reduce intraoperative blood loss are usually 
applied in the contemporary surgical procedures and more strict criteria for 
perioperative blood transfusion than in the past are followed, the administration 
of blood has decreased. Frequently, this leads to more excessive amounts of 
blood cross matched. As blood typing and cross matching places a specified 
number of units of allogeneic blood on reserve for an individual patient, these 
cross matched units cannot be transfused into another as long as they are still 
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on reserve for a specific patient. To meet the vast reserve demands, blood bank 
inventories must increase. As shown in the study from Jennings [63], the longer 
a unit of blood remains on reserve, the less likely it will be transfused and the 
greater the probability it will become outdated and be discarded. This wasteful 
practice should be avoided to save the limited medical resources.    
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2. Purpose 
 
                This study aims to determine the need for perioperative allogeneic 
blood transfusion in patients with squamous cell carcinoma of the oral cavity 
who underwent curative surgical procedures and to develope a Transfusion 
Prediction Model (TPM). With this model, the surgeon can predict the likelihood 
of receiving perioperative blood transfusion in certain patients and can make a 
decision together with the anesthesiologist regarding the general conditions of 
the patient on preparing for managements of perioperative blood loss. 
Furthermore, the surgeon can also educate the patient about the likelihood of 
receiving perioperative blood transfusion and according risks of allogeneic 
blood and the alternatives to allogeneic blood transfusion such as acute 
normovolemic hemodilution, as the current regulations in blood transfusion of 
the University Hospital of Muenster [122] do not recommend the use of 
preoperative autologous blood donation in tumor patients. By being educated, 
patients can make a decision regarding the need and possibility for acute 
normovolemic hemodilution or the likelihood of receiving allogeneic blood. 
Furthermore, the routine type and screen or type and crossmatch procedures 
can be limited only to those patients who are likely to need blood transfusions.  
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3. Materials and Methods 
  
 
                The data from all consecutive patients with squamous cell carcinoma 
of the oral cavity who underwent curative surgical procedures at the Department 
of Cranio- and Maxillofacial Surgery, University of Muenster during 1998-2002 
were retrospectively collected. 
 
3.1. Including criteria 
 
1.  primary squamous cell carcinoma of the oral cavity  
2.  primary surgical treatment without any other preoperative treatment, such as 
     preoperative radiotherapy or chemotherapy                              
3.  curative surgery 
4.  complete documentation of patient’s data 
 
3.2. Excluding criteria 
   
1.  recurrent or metastatic squamous cell carcinoma 
2.  other types or sites of tumors 
3.  palliative surgery 
4.  patient with any other previous treatments such as radiotherapy or   
     chemotherapy 
5.  missing of important data  
 
                The attending surgeons were all faculty from the department. In all 
patients, the preoperative diagnoses were confirmed by biopsy and subsequent 
pathohistologic examination. 
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3.3. Data collection and definition 
 
                All data were collected retrospectively from anesthetic records and 
patient’s charts by using Excel 2000 program. The data include the followings.  
 
1.  patient’s age at the time of surgery  
2.  gender  
3.  weight in kilogram at the time of surgery 
4.  associated diseases and debilitating factors 
     - cardiovascular diseases 
     - pulmonary diseases 
     - endocrinological diseases 
     - gastrointestinal diseases  
     - urogenital diseases 
     - alcohol abuse 
     - smoking  
     - others 
5.  tumor site 
     - anterior floor of the mouth                   
     - posterior floor of the month 
     - alveolar process 
     - hard and soft palate 
     - pharynx, tonsil, retromolar region 
6.  tumor size : according to pathological TNM classification (UICC) 
     - pT1 
     - pT2 
     - pT3 
     - pT4 
7.  lymph node involvement: according to pathological TNM classification 
(UICC) 
     - pNx 
     - pNo 
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     - pN1 
     - pN2 
     - pN3 
8.  duration of surgery  
9.  tracheostomy 
     - without tracheostomy 
     - primary tracheostomy ; defined as an intraoperative tracheostomy 
     - secondary tracheostomy ; defined as an postoperative tracheostomy 
10. type of tumor resection 
     - without bony resection 
     - with partial mandibulectomy / maxillectomy without  continuity defect 
     - with partial mandibulectomy / maxillectomy with continuity defect 
11. type of immediate reconstruction   
     - local closure without flap reconstruction 
     - partial thickness skin graft 
     - local flap     
     - distant flap 
     - microvascular free flap  
12. neck dissection 
     - without neck dissection 
     - unilateral neck dissection 
     - bilateral neck dissection 
13. preoperative hemoglobin (g/dl) and hematocrit levels (%) 
14. amount of cross matched packed red cell (unit) 
15. amount of transfusion (unit) 
     - packed red cell 
     - platelets concentrate 
     - fresh frozen plasma 
16. period of transfusion 
     - preoperative 
     - intraoperative 
     - postoperative 
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17. presence of informed consent for blood transfusion 
     - by anesthesiologist 
     - by surgeon 
 
                Normal hemoglobin levels in this setting for males were 14 -18 g/dl 
and for females were 12 -16 g/dl. A perioperative blood transfusion was defined 
as the transfusion of allogeneic blood before, during surgery or within the 
hospital stays. The decision for transfusion was made by either attending 
surgeon or anesthesiologist. A general guideline for transfusion of packed red 
cell was a hemoglobin level under 8 g/dl with deteriorated cardiovascular status 
in spite of adequate intravascular volume. However, multiple factors were also 
considered such as age and underlying diseases of the patient. 
 
 
3.4. Statistical considerations 
 
                All 17 variables were descriptively analyzed to describe the 
population. When undertaking the analyses to determine influential variables in 
predicting the need for transfusion, only 10 variables available before the 
surgical procedure were examined. They include age, gender, weight, 
associated diseases, tumor site, tumor size, type of tumor resection, type of 
immediate reconstruction, neck dissection and preoperative hemoglobin level. 
The relationship between these variables and blood transfusion need was 
evaluated with step back logistic regression model using a p-value of less than 
0.05 as significant. The significant variables from the last step of the first logistic 
regression were analyzed further in second and third logistic regression using 
also a p-value of less than 0.05 as significant. The logistic regression program 
allowed calculation of the probability of transfusion need based on the 
significant predictive variables. Finally, the predictability of the significant 
variables was also quantified by using the area under the Receiver Operating 
Characteristic curve (ROC area). Data were processed using SPSS / PC+ 
version 12. 
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4. Results 
 
 
4.1. Biographic data 
 
Age and gender 
                From the total amount of 150 patients, age range was 33 – 89 years 
with the mean age of 61 years. One hundred and three patients (68.7%) were 
male and 47 (31.3%) were female (Table 1). 
 
 
 
Gender  
Age (year) male female 
 
total 
30-39 1 3 4 (2.7%) 
40-49 14 6 20 (13.3%) 
50-59 27 8 35 (23.3%) 
60-69 48 15 63 (42.0%) 
>=70 13 15 28 (18.7%) 
total 103 (68.7%) 47 (31.3%) 150 (100.0%) 
 
Table 1. Age and gender 
 
 
Weight   
              The weight of patients at the time of surgery ranged from 45 – 116 
kg., with the mean weight of 73.5 kg.  
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Associated diseases and debilitating factors 
                The most frequent associated diseases were cardiovascular diseases 
(46%), followed by pulmonary (20.7%), and endocrinological diseases (15.3 %), 
respectively. About 75 % of the patients had history of smoking, while 56 % had 
alcohol abuse (Figure 1). 
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Figure 1. Associated diseases and debilitating factors (n =150)  
 
 
4.2. Tumor data 
 
Tumor site 
                The most common primary tumor sites were the anterior floor of the 
mouth (39.3%) and the posterior floor of the mouth (34.7%), followed by the 
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tongue, the alveolar process, pharynx/tonsil/retromolar area. The least common 
sites were palate and buccal mucosa (Figure 2). 
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Figure 2. Tumor site 
 
 
Pathological TNM stage  
                The majority of the patients had T1 – T2 tumors (80.7%), while 29 
patients had T3 – T4 tumors (19.4%). Ninety patients were neck stage N0 (60 
%), 22 were N1 (14.7%), 12 were N2 (8.0%), while there was no patient with N3 
disease and 26 patients (17.3%) did not receive neck dissection (Table 2).  
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N0 N1 N2 N3 Nx total 
T1 51 8 0 0 17 76 
T2 25 8 5 0 7 45 
T3 2 1 3 0 1 7 
T4 12 5 4 0 1 22 
total 90 22 12 0 26 150 
 
Table 2. Number of patients according to pathological TNM stage 
 
 
4.3. Operation data 
                     
Duration of surgery          
                The procedures were longer than 6 hours in 44 % of the patients 
while 15.3% of the patients experienced the procedures that took 2 hours or 
shorter (Table 3). 
 
 
 
Duration (minute) Number of patient % 
<  60 8 5.3 
60 - 119 15 10.0 
120 - 239 32 21.3 
240 - 359 26 17.3 
360 - 479 25 16.7 
> 480 44 29.3 
total 150 100.0 
 
Table 3. Duration of surgery 
 
Results 
 26 
 
Tracheostomy 
                Primary tracheostomy was performed in 14 patients (9.3%) and 
secondary tracheostomy in 22 patients (14.7%). The majority or 114 patients 
(76%) were not received tracheostomy (Figure 3). 
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Figure 3. Need for tracheostomy 
 
 
Type of tumor resection   
                Tumor resection without jaw bone resection was performed in 43 
patients (28.7%), while jaw resection without continuity defect was performed in 
38 patients (25.3%). Forty six percent of patients received jaw resection with 
continuity defect (Figure 4). 
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Figure 4. Type of tumor resection 
 
 
 
Type of reconstruction  
                All of the continuity defects of the mandible were maintained and 
stabilized with titanium reconstruction plates. All of the bony defects in maxilla 
were left open and subsequently treated with obturator prosthesis. 
 
                The soft tissue defects were locally closed without any reconstruction 
in 70 patients (46.7%), followed by microvascular free flaps in 53 patients (35.3 
%), local flaps in 15 patients (10.0%), partial thickness skin grafts in 10 patients 
(6.7%), and distant flaps in 2 patients (1.3%).(Figure 5) 
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Figure 5. Type of reconstruction 
 
  
 
Neck dissection 
                Unilateral neck dissection was performed in 93 patients (62%), while 
27 patients (8 %) were received bilateral neck dissections. In 30 patients (20%), 
the neck dissection was not necessary (Figure 6). 
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Neck dissection
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Figure 6. Need for neck dissection 
 
 
4.4. Laboratory data 
 
 Preoperative hemoglobin level 
                From 150 patients, 35 (23.3%) had preoperative hemoglobin under 
normal values. Among them, 32 were male and 3 were female (Table 4).  
 
 
Hemoglobin level 
(Hb) 
Male Female Total 
normal Hb 71  (47.4%) 44  (29.3%) 115   (76.7%) 
under normal Hb 32  (21.3%)     3   (2.0%)      35   (23.3%) 
Total 103 (68.7%) 47  (31.3%)    150 (100.0%) 
 
Table 4. Preoperative hemoglobin level 
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4.5. Transfusion Data            
 
Transfusion requirements 
                The overall transfusion rate for all blood products was 41 (27.3%) of 
150 patients. All of them were transfused with packed red cell, 3 of them were 
additionally transfused with fresh frozen plasma and 1 patient received 1 unit of 
platelets concentrate additionally (Table 5, 6). 
 
 
 
Blood products Number of patients Unit 
packed red cell 41 (27.3%) 108 
fresh frozen plasma 3 (2.0%) 13 
platelets concentrate 1 (0.7%) 1 
 
Table 5. The overall transfusions for all types of blood products 
 
 
 
Type of 
transfusion 
Number of 
patients 
Percent of total 
patients 
Percent of 
transfused 
patients 
PRC only 37           24.6 90.3 
PRC + FFP 3 2.0   7.3 
PRC + Plt 1 0.7 2.4 
Total 41          27.3         100.0 
 
Table 6. Number of patients transfused with varying blood products;  
PRC = packed red cell, FFP = fresh frozen plasma, Plt = platelets concentrate 
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                The total amount of transfused packed red cell was 108 units, making 
an average amount of red cell transfusion of 2.6 units per patient transfused. 
Blood typing and cross matching were performed in 135 patients, while only 41 
patients (30.4%) were transfused. Among patients who received blood 
transfusion, 28 were transfused with 2 units, 6 were with 4 units, 3 were with 3 
units, and 1 was with 1 unit of blood, only 3 patients needed more than 4 units 
of blood. (Table 7) The total amount of preoperatively cross matched packed 
red cell was 501 units, while only 108 units were transfused, making the 
crossmatch to transfusion ratio of 4.7:1. 
 
 
 
Amount (unit) Number of patient % 
0 109 72.7 
1 1 0.7 
2 28 18.7 
3 3 2.0 
4 6 4.0 
5 1 0.7 
6 1 0.7 
7 1 0.7 
total 150 100.0 
 
Table 7. Transfusion requirement (units of packed red cell)   
 
 
Period of transfusion 
                From 41 patients who were transfused with red blood cell, 28 
received transfusion postoperatively, 8 intraoperatively and 3 were transfused 
both intra- and postoperatively. In 2 patients, the data were missing. 
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Informed consent for blood transfusion    
                One hundred and forty seven patients were informed from the 
anesthesiologists about the probability of perioperative allogeneic blood 
transfusion. Only 21 of them were additionally informed by the surgeons. In 3 
patients, the consent forms were missing. (Figure 7) 
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Figure 7. Number of patients who were informed about transfusion by 
anesthesiologist, anesthesiologist and surgeon 
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4.6. Transfusion Prediction Model ( TPM ) 
 
              The 10 variables with several further subcategories, which could be 
acquired before surgery, were analyzed with the step back logistic regression to 
determine the significance as predictive factors for the transfusion requirement. 
After each step of the first logistic regression, the variable or subcategory which 
was least significant was deleted from the list of variables, and the others were 
analyzed further in the next step. After 20 steps of the first logistic regression, 
only weight, type of immediate reconstruction and neck dissection were 
determined as significant (p< 0.05). (Table 8) 
 
 
Variables p-value 
age >0.05 
gender >0.05 
weight 0.04 
associated diseases >0.05 
tumor sites >0.05 
tumor size >0.05 
type of tumor resection >0.05 
type of reconstruction 0.00 
   -skin graft 0.99 
   -local flap 0.99 
   -distant flap 0.99 
   -microvascular free flap 0.99 
need for neck dissection 0.02 
hemoglobin level >0.05 
 
Table 8. Result of the first logistic regression analysis 
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                As the subcategories of immediate reconstruction did not have any 
significance on the transfusion requirement, as shown in Table 8, this variable 
was newly named as the need for reconstruction and then divided only into two 
subcategories; with or without soft tissue reconstruction. These three significant 
variables, weight, neck dissection and immediate reconstruction, were then put 
into the second logistic regression analysis to testify their significance. Using a 
p-value of less than 0.05 as significant, weight of the patient has lost its 
significance, while neck dissection and reconstruction were still considered as 
significant factors after the second logistic regression (Table 9). These 2 factors 
were then put into the third logistic regression analysis to testify their 
significance again and to provide the calculation of the Transfusion Prediction 
Model (TPM). After the third logistic regression, using also a p-value of less 
than 0.05 as significant, the need for neck dissection and the need for 
reconstruction were still considered as influential factors for blood transfusion 
requirement. Among these 2 variables, the need for reconstruction showed 
higher significance than the need for neck dissection (Table 9).  
 
 
 
Variables p-value 
weight 0.353 
need for reconstruction 0.000 
need for neck dissection 0.047 
 
Table 9. Result of the second and third logistic regression analyses 
 
 
                The logistic regression program yielded the following Transfusion 
Prediction Model (TPM):  
 
                       Risk= exp (z) / [1 + exp (z)] 
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    when z = - 4.025 + 2.805 * (immediate reconstruction) + 0.969 * (neck 
dissection). 
 
    The variables took the following values: 
 
                immediate reconstruction :  0 = no  , 1 = yes 
                neck dissection                 :  0 = no  , 1 = unilateral , 2 = bilateral 
 
                The predicted probability for transfusion was calculated from the 
logistic regression equation and the results are shown in Table 10. 
 
 
 
 
 
 
 
 
 
 
Table 10. Transfusion Prediction Model (TPM) shows the calculated probability                
               for transfusion based on multivariate analysis with logistic regression             
               model. 
 
 
                From the calculated probability for transfusion, it showed that patients 
who required bilateral neck dissection and immediate reconstruction will have 
the greatest probability of requiring a perioperative blood transfusion (67.2%). 
Patients who required neither neck dissection nor immediate reconstruction will 
have the lowest probability (1.7%) to receive blood transfusion. 
 
Neck dissection  Type of 
reconstruction 
no unilateral bilateral 
without 
reconstruction 1.7% 4.5% 11.2% 
with reconstruction 22.7% 43.7% 67.2% 
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                Additionally, the values of sensibility were plotted against the values 
of 1-specificity for construction of the Receiver Operating Characteristic (ROC) 
curve as shown in Figure 8. The area under the ROC curve (ROC area) for the 
neck dissection and the need for reconstruction were 0.674 and 0.771 
respectively.  
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Figure 8. The ROC curve for neck dissection and reconstruction 
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5. Discussion 
    
5.1. Transfusion requirements 
 
                 In this study, the overall transfusion rate was 27.33%. It is lower than 
in the study from Taniguchi and Okura [128], who found the transfusion rate in 
their study to be 61% of 105 patients. However, all patients in their study had 
stage II - IV oral squamous cell carcinoma. Weber [138] found the overall 
transfusion rate in patients with all stages of various head and neck tumors to 
be 11.57% of 436 patients. However, the majority of them (77%) did not receive 
reconstruction and 30.7% did not receive neck dissection. Recently, Habler et 
al. [53] performed a prospective study on preoperative hemodilution in patients 
who underwent major maxillofacial surgery. Forty six from 84 tumor patients 
(55%), who received major resection, bilateral neck dissection and immediate 
reconstruction, were transfused. 
 
                A crossmatch to transfusion ratio of 4.7: 1 in this study is considered 
as very high when compared to other studies. McCulloch et al. [84] reported a 
crossmatch to transfusion ratio of 2.8: 1 in 77 patients with major surgical 
resections for head and neck carcinoma, while Leong and Chew [74] found this 
ratio to be 3.1: 1 in their retrospective study with 63 patients undergoing a 
variety of head and neck cancer operations. At a crossmatch to transfusion ratio 
of 4.7: 1, there remains a substantial amount of waste, that is, nearly 5 units of 
blood are cross matched and removed from the available blood pool for every 
unit transfused. In this era of limited medical resources, this wasteful practice is 
unacceptable. 
 
                  From 135 patients who underwent blood typing and cross matching 
for allogeneic blood, only 41 (30.37%) of them were transfused. That means, 
about 70% of these procedures were wasteful. 
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                  From 41 patients who received allogeneic blood transfusion, the 
majority of them (68.3%) received 2 units of blood. This is comparable to the 
study from McCulloch et al. [84], who found in their study that 65% of their 
patients required less than 2 units of bloods. Similarly, Weber [138] found in his 
study that 36 (75.6%) of 51 patients who required transfusion, were transfused 
with 2 or fewer units of blood. Krupp et al [69] also found in their study that the 
majority (56.25%) of their patients with all stages of head and neck tumors, who 
required transfusion, were transfused with 2 units of blood. This information 
make the preoperative autologous blood donation a possible alternative to 
allogeneic blood use, providing that the patients meet the requirements for 
autologous blood donation and the preoperative time interval allow the 
procedure possible. However, the current regulations in blood transfusion of the 
University Hospital of Muenster [122] do not recommend the use of 
preoperative autologous blood donation in tumor patients. These regulations, 
however, should be reevaluated in the aspect of performing preoperative 
autologous blood donation due to many reasons. First, there are a lot of 
evidences of the deleterious effect of allogeneic blood transfusion on survival 
and recurrence in tumor patients in varying studies, as mentioned previously 
[44, 20, 42, 14, 59, 72, 129, 130, 114, 64, 62, 66, 142, 9, 4, 128].  Second, there 
are several studies, which reported a positive effect of autologous blood 
transfusion on survival and recurrence rate in tumor patients with varying 
settings when compared with allogeneic blood transfusion. Motoyama et al. [93] 
found the survival advantage of using autologous blood transfusion for 
esophageal cancer when compared with patients who received allogeneic blood 
transfusion. In another study from Motoyama et al. [92], they concluded in their 
study that use of autologous instead of allogeneic blood transfusion during 
esophagectomy prolonged disease-free survival among patients with recurrent 
esophageal cancer. Takemura et al. [127] recently reported immunologic effects 
of allogeneic versus autologous blood transfusion in patients undergoing radical 
esophagectomy. They found postoperative decrease of CD4+ lymphocyte count 
and NK cell activity in patients who received blood transfusion, however these 
abnormalities were returned to normal two weeks later in patients who received 
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autologous blood transfusion, but not in patients who received allogeneic blood. 
They also found a higher rate of infectious complications in allogeneic 
transfusion than in autologous transfusion group. In head and neck cancer 
surgery, Moir et al. [90] found a recurrent rate of 59% in head and neck cancer 
patients who received allogeneic blood transfusion compared with recurrent 
rates of 33% and 35% in those who had received autologous blood and those 
who did not receive transfusion at all in the same patient group. They also 
concluded that autologous blood should be used during head and neck cancer 
surgery if possible when transfusion is necessary. Third, the tumor patients 
should also have the same opportunity as other patients to use autologous 
blood to avoid risks from allogeneic blood, if the situation allows. 
 
                  There are several authors who reported the use of autologous blood 
in head and neck tumor surgery [90, 118, 55]. Several found the majority of their 
tumor patients could have met all criteria for preoperative autologous blood 
donation. Leong and Chew [74] found 62% of their patients met the criteria for 
preoperative autologous blood donation and 50% of the patients’ total 
transfusion requirements could have been covered by predeposited blood. In a 
similar study, McCulloch et al. [84] reviewed 77 patients undergoing head and 
neck surgical procedures. In their study, 85% of patients met the criteria for 
autologous blood donation, and 65% could have met all their perioperative 
blood needs through autologous donation. The authors concluded that 
preoperative autologous blood donation is an effective alternative to allogeneic 
transfusion in most head and neck surgical procedures. In the study from 
Weber [138], 52% of the patients receiving allogeneic transfusion could have 
met all their transfusion requirements through autologous donation. 
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5.2. Transfusion Prediction Model ( TPM ) 
  
                   In this study, only the need for neck dissection and the need for 
reconstruction were found to be significant variables contributing to transfusion 
requirement. Several investigators had also investigated the factors that may 
have influence on transfusion requirement and they found varying results. 
Rashiq et al. [111] found age, gender, weight, hemoglobin level, ASA status and 
revision surgery to be the predictors for the blood transfusion in total joint 
arthroplasty. Karkouti et al. [67] created a multivariable model consisting of age, 
gender, weight, and hemoglobin level for predicting the need for blood 
transfusion in patients undergoing coronary bypass graft surgery. Benoist et al. 
[11], using multivariate analysis, defined age, body mass index, hemoglobin 
level, ASA status, and additional surgical procedures as significant risk factors 
for perioperative blood transfusion in patients with colorectal carcinoma. In 
contrast, Ferraris and Gildengorin [39], found only bleeding time and red cell 
volume were the best predictors for blood use among 12 variables. 
 
                   In this study, the multivariate logistic regression analysis 
demonstrated the need for reconstruction and the need for neck dissection to 
be significant in predicting the transfusion requirement. Other studies, which 
were performed in patients with head and neck tumors, found that similar 
factors were associated with an increased risk for transfusion. Von Doersten et 
al. [133] found that a low preoperative hemoglobin level, pharyngeal tumor site, 
and stage III disease were predictors of the need for blood transfusion. Boeck et 
al. [18] found a low preoperative hemoglobin level, higher-stage tumors and the 
need for neck dissection to be significant for transfusion requirement. Weber 
[138] investigated preoperative clinical and laboratory variables to predict the 
transfusion requirement in patients  underwent major oncologic procedures for 
all stages of various head and neck tumors and reported tumor size, flap 
reconstruction, and a low preoperative hemoglobin level as significant variables 
in predicting the transfusion requirement . In this study, in contrast to those 
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studies, tumor site, tumor size, and a low preoperative hemoglobin level were 
not proved to have significant relationship to the needs of blood transfusion.  
 
                The ability of the TPM to predict the risk of requiring transfusion was 
quantified by the area under the Receiver Operating Characteristic curve (ROC 
area). The ROC area can range from 0.5 (not more predictive than a coin flip) to 
1.0 (perfect discrimination). A value over 0.7 can be interpreted as fair, and over 
0.8 as good. When considering the ROC area in this study, which was 0.67 for 
the need of neck dissection and 0.77 for the need for reconstruction, one can 
assume the ability of TPM to be fair in predicting the transfusion requirement.   
 
 
5.3. Potential uses of the Transfusion Prediction Model in clinical 
practice 
 
                The risk of blood transfusion calculated from the TPM could be 
applied to daily clinical practice in many aspects. 
 
                 According to the regulations in blood transfusion of the University 
Hospital of Muenster, surgeon must include the probability and risks of blood 
transfusion in the preoperative consent form, if the risk of requiring blood 
transfusion is 10% or higher for any surgical procedures [122]. According to the 
TPM, it might be necessary for surgeons to inform oral cancer patients about 
the probability and associated risks of transfusion when bilateral neck dissection 
or any type of immediate reconstruction is anticipated. 
 
                  Until currently, there is only a crude suggestion in the Department of 
Cranio-and Maxillofacial Surgery, University Hospital of Muenster that surgeon 
should order 2 units of packed red cell per one side of anticipated neck 
dissection. This led to a general practice of routine crossmatch for 2 units in 
patients who would undergo a unilateral neck dissection, and 4 units in those 
who would receive bilateral neck dissection, whether a reconstruction would be 
performed or not. This practice may have led to a high crossmatch to 
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transfusion ratio in this study, as the TPM has shown that the need for 
reconstruction was more significant than the need for neck dissection in 
predicting of transfusion requirement. 
 
                    From the data of transfusion requirements in this study together 
with the result from TPM, a guideline for preparing of blood for perioperative use 
in patients with oral squamous cell carcinoma should be developed. 
 
                 If the risk for requiring transfusion is low, that is, less than 10%, it 
may be not necessary to perform blood typing and screening. For patients who 
have a moderate risk for transfusion (between 10% and 20%), a preoperative 
type and screen should be performed. When the risk of requiring blood 
transfusion is high (20% or greater), preoperative planning should include type 
and crossmatch for 2 units of packed red cell, acute normovolemic 
hemodilution, or a preoperative autologous blood donation for 2 units of blood, if 
the regulations in blood transfusion allow (Table 11). 
 
 
Table 11. Preoperative transfusion planning based on TPM;  
                ANH = acute normovolemic hemodilution 
                PABD = preoperative autologous blood donation 
                * = if the regulations in blood transfusion allow 
 
Neck dissection  Type of 
reconstruction 
no unilateral bilateral 
without 
reconstruction 
no type &  
screen 
no type & 
screen type & screen 
with 
reconstruction 
type and 
crossmatch or 
ANH or PABD* 
type and 
crossmatch or 
ANH or PABD* 
type and 
crossmatch or 
ANH or PABD* 
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                If the regulations allow a preoperative autologous blood donation in 
tumor patients, it should be performed in those patients, who have risk for 
transfusion of 20% or greater, to avoid discarding of these autologous units. In 
this case, TPM would be very useful to identify this group of patients. 
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6. Conclusion 
 
In contemporary oral and maxillofacial cancer surgery, blood 
transfusions have expanded surgeons’ ability to safely resect oral cancer and 
perform major reconstructive procedures. Nevertheless, blood transfusions also 
possess many risks such as transfusion reactions, transmission of infections, 
and immunosuppressive effects, which may lead to higher recurrence rate and 
short disease-free interval. These adverse effects of allogeneic blood 
transfusion have led surgeons and anesthesiologists to become more cautious 
in their use of transfusion. Intraoperative techniques for reduction of blood loss, 
strict guidelines for blood transfusion, acute normovolemic hemodilution and 
use of autologous blood donation are among the methods used to decrease the 
need of allogeneic blood. In the current situation of cost constraint and resource 
conservation, it is necessary to develope a predictive model to determine the 
risk for transfusion. With this model, the routine type and screen or type and 
crossmatch procedure can be limited only to those patients who are likely to 
require transfusion. Moreover, if the acute normovolemic hemodilution or 
autologous blood donation should be performed, this predictive model could be 
useful in selecting appropriate group of patients for these procedures according 
to cost-effectiveness basis. 
 
                 In this retrospective study including 150 patients undergoing surgical 
treatment for oral squamous cell carcinoma, the need for neck dissection and 
the need for reconstruction were found to be the influential factors for requiring 
blood transfusion, as shown by logistic regression analysis. As a result, a TPM 
was developed to assist in preoperative planning for blood transfusion. With this 
model, it is possible to identify patients who have low, intermediate and high risk 
for requiring blood transfusion, making an appropriate and cost-effective 
preoperative planning for blood transfusion possible. 
 
                   In order to prove, and if necessary, improve the accuracy of this 
predictive model, it is necessary to compare the predicted transfusion rate with 
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the actual transfusion rate in a new prospective study of patients undergoing 
oncologic procedure for oral squamous cell carcinoma. If the TPM proves to be 
accurate, it may aid clinician in more cost-effective preoperative planning for 
blood transfusion. 
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Pathological TNM Classification for oral squamous cell carcinoma (UICC) 
 
Primary tumor (pT)       
pTx   = primary tumor cannot be assessed 
pT0   = No evidence of primary tumor 
pTis  = Carcinoma in situ 
pT1  = Tumor 2 cm or less in greatest dimension 
pT2  = Tumor more than 2 cm but not more than 4 cm in greatest dimension 
pT3  = Tumor more than 4 cm in greatest dimension 
pT4  = (lip) Tumor invades adjacent structures( e.g. through cortical bone, 
            tongue, skin of neck)              
           (oral cavity) Tumor invades adjacent structures (e.g. through cortical          
            bone, into deep (extrinsic) muscle of tongue, maxillary sinus, skin) 
 
Regional lymph nodes (pN) 
pNx  = Regional lymph nodes cannot be assessed 
pN0 = No regional lymph node metastasis 
pN1  = Metastasis in a single ipsilateral lymph node, 3 cm or less in  
             greatest dimension 
pN2  = Metastasis in a single ipsilateral lymph node, more than 3 cm but not 
            more than 6 cm in greatest  dimension; or in multiple 
            ipsilateral lymph nodes, none more than 6 cm in greatest 
            dimension; or in bilateral or contralateral lymph nodes, none 
            more than 6 cm in greatest dimension                          
            pN2a  = Metastasis in single ipsilateral lymph node more than 3 cm  
                          but  not more than 6 cm in greatest dimension  
            pN2b  = Metastasis in multiple ipsilateral lymph nodes, none more 
                          than 6 cm in  greatest dimension 
Appendix 
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            pN2c  = Metastasis in bilataral or contralateral lymph nodes, none  
                          more than 6 cm in greatest dimension 
                           
pN3  = Metastasis in a lymph node more than 6 cm in greatest dimension  
 
Distant metastasis (M) 
Mx  = Presence of distant metastasis cannot be assessed  
M0  = No distant metastasis 
M1  = Distant metastasis 
 
Stage grouping 
 
Stage 0      Tis           N0            M0 
Stage 1      T1            N0            M0 
Stage 2      T2            N0            M0 
Stage 3      T3            N0            M0 
                  T1            N1            M0 
                  T2            N1            M0 
                  T3            N1            M0 
Stage 4      T4            N0            Mo 
                  T4            N1            M0 
                  AnyT        N2            M0 
                  AnyT        N3            M0 
                  AnyT        AnyN        M1  
 
 
 
 
 
